Savara (SVRA) Payables (2010 - 2026)
Savara (SVRA) posted quarterly Payables of $4.5 million for Q1 2026, down 19.09% year-over-year from $5.6 million in Q1 2025, and down 21.9% quarter-over-quarter from $5.8 million in Q4 2025.
Savara (SVRA) Payables (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Payables for 17 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 19.09% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (down 19.09% YoY), while the FY2025 annual figure was $5.8 million, up 26.67% from the prior year.
- Payables slipped to $4.5 million in Q1 2026 per SVRA's latest filing, from $5.8 million in the prior quarter.
- Across five years, Payables topped out at $5.8 million in Q4 2025 and bottomed at $805000.0 in Q2 2022.
- Historically, Payables has averaged $3.2 million across 5 years, with a median of $3.4 million in 2024.
- Annual changes were most pronounced in 2022 — Payables tumbled 62.45% — and 2023, when it surged 260.47%.
- Savara's Payables stood at $1.3 million in 2022, then jumped by 162.67% to $3.5 million in 2023, then climbed by 29.71% to $4.5 million in 2024, then increased by 26.67% to $5.8 million in 2025, then decreased by 21.9% to $4.5 million in 2026.
- Business Quant data shows SVRA's Payables at $4.5 million in Q1 2026, $5.8 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.00 Mn |
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 5.76 Mn |
| Sep 30, 2025 | 4.14 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 5.56 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 4.61 Mn |
| Jun 30, 2024 | 3.39 Mn |
| Mar 31, 2024 | 2.85 Mn |
| Dec 31, 2023 | 3.50 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | 1.33 Mn |
| Sep 30, 2022 | 893,000.00 |
| Jun 30, 2022 | 805,000.00 |
| Mar 31, 2022 | 1.30 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Sep 30, 2021 | 1.28 Mn |